Hepatitis C virus: Virology, diagnosis and management of antiviral therapy

被引:103
作者
Chevaliez, Stephane
Pawlotsky, Jean-Michel
机构
[1] Univ Paris 12, Hop Henri Mondor, Dept Virol, French Natl Reference Ctr Viral Hepatitis B C & D, F-94010 Creteil, France
[2] Univ Paris 12, Hop Henri Mondor, INSERM, U841, F-94010 Creteil, France
关键词
hepatitis C virus; serological tests; hepatitis C virus genotype; HCV RNA quantification; interferon alpha; ribavirin;
D O I
10.3748/wjg.v13.i17.2461
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) infects approximately 170 million individuals worldwide. Prevention of HCV infection complications is based on antiviral therapy with the combination of pegylated interferon alfa and ribavirin. The use of serological and virological tests has become essential in the management of HCV infection in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. Anti-HCV antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. The HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, most importantly the sustained virological response, i.e. the endpoint of therapy. (C) 2007 The WIG Press. All rights reserved.
引用
收藏
页码:2461 / 2466
页数:6
相关论文
共 32 条
  • [1] [Anonymous], 1999, J Hepatol, V30, P956
  • [2] [Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
  • [3] Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
    Castéra, L
    Vergniol, J
    Foucher, J
    Le Bail, B
    Chanteloup, E
    Haaser, M
    Darriet, M
    Couzigou, P
    De Lédinghen, V
    [J]. GASTROENTEROLOGY, 2005, 128 (02) : 343 - 350
  • [4] CHEVALIEZ S, 2007, IN PRESS HEPATOLOGY
  • [5] Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    Chung, RT
    Andersen, J
    Volberding, P
    Robbins, GK
    Liu, T
    Sherman, KE
    Peters, MG
    Koziel, MJ
    Bhan, AK
    Alston, B
    Colquhoun, D
    Nevin, T
    Harb, G
    van der Horst, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) : 451 - 459
  • [6] Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature
    Colin, C
    Lanoir, D
    Touzet, S
    Meyaud-Kraemer, L
    Bailly, F
    Trepo, C
    [J]. JOURNAL OF VIRAL HEPATITIS, 2001, 8 (02) : 87 - 95
  • [7] Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
    Dalgard, O
    Bjoro, K
    Hellum, KB
    Myrvang, B
    Ritland, S
    Skaug, K
    Raknerud, N
    Bell, H
    [J]. HEPATOLOGY, 2004, 40 (06) : 1260 - 1265
  • [8] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Davis, GL
    Wong, JB
    McHutchison, JG
    Manns, MP
    Harvey, J
    Albrecht, J
    [J]. HEPATOLOGY, 2003, 38 (03) : 645 - 652
  • [9] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
  • [10] Automated sample preparation for the TRUGENE HIV-1 genotyping kit using the MagNA Pure LC instrument
    Germer, JJ
    Vandenameele, JN
    Mitchell, PS
    Harmsen, WS
    Yao, JDC
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (01) : 59 - 61